Fintel reports that on October 6, 2025, JMP Securities upgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Market Perform to Market Outperform.
Analyst Price Forecast Suggests 81.78% Upside
As of September 30, 2025, the average one-year price target for Intellia Therapeutics is $36.28/share. The forecasts range from a low of $8.08 to a high of $111.30. The average price target represents an increase of 81.78% from its latest reported closing price of $19.96 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Intellia Therapeutics is 126MM, an increase of 139.29%. The projected annual non-GAAP EPS is -6.24.
What is the Fund Sentiment?
There are 496 funds or institutions reporting positions in Intellia Therapeutics. This is an decrease of 39 owner(s) or 7.29% in the last quarter. Average portfolio weight of all funds dedicated to NTLA is 0.08%, an increase of 5.32%. Total shares owned by institutions decreased in the last three months by 4.83% to 120,806K shares. 
The put/call ratio of NTLA is 0.37, indicating a bullish outlook.
What are Other Shareholders Doing?
ARK Investment Management holds 13,018K shares representing 12.13% ownership of the company. In its prior filing, the firm reported owning 13,011K shares , representing an increase of 0.05%. The firm decreased its portfolio allocation in NTLA by 3.31% over the last quarter.
ARKK - ARK Innovation ETF holds 9,550K shares representing 8.90% ownership of the company. In its prior filing, the firm reported owning 8,484K shares , representing an increase of 11.16%. The firm decreased its portfolio allocation in NTLA by 6.47% over the last quarter.
Regeneron Pharmaceuticals holds 3,703K shares representing 3.45% ownership of the company. No change in the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,236K shares representing 3.01% ownership of the company. In its prior filing, the firm reported owning 3,131K shares , representing an increase of 3.22%. The firm increased its portfolio allocation in NTLA by 21.62% over the last quarter.
ARKG - ARK Genomic Revolution ETF holds 2,899K shares representing 2.70% ownership of the company. In its prior filing, the firm reported owning 2,874K shares , representing an increase of 0.85%. The firm increased its portfolio allocation in NTLA by 24.78% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
